-- Presentation to be webcast on www.exelixis.com
--
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 3, 2014--
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s president and chief executive officer, will provide
an overview of the company at the Goldman Sachs 35th Annual
Global Healthcare Conference taking place next week in Rancho Palos
Verdes, California. The Exelixis presentation is scheduled for 12:20
p.m. EDT/9:20 a.m. PDT on Tuesday, June 10, 2014.
The presentation will be webcast live and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Please connect to the company’s website at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may
be required to listen to the webcast.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily
on COMETRIQ® (cabozantinib), its wholly-owned inhibitor
of multiple receptor tyrosine kinases. Another Exelixis-discovered
compound, cobimetinib, a highly selective inhibitor of MEK, is being
evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in
a broad development program under a collaboration with Exelixis. For
more information, please visit the company's web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
trademarks.
Source: Exelixis, Inc.
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor
Relations & Corporate Communications
shubbard@exelixis.com
